Exhibit 99.1

   Interleukin Achieves Milestone in Nutrigenomics Collaboration with Alticor

    WALTHAM, Mass.--(BUSINESS WIRE)--March 16, 2004--Interleukin
Genetics, Inc. (OTCBB: ILGN) reported today that it has signed a
Distribution Agreement with Access Business Group International LLC, a
subsidiary of Alticor Inc., for DNA-based risk assessment tests.
    With the execution of this agreement, Interleukin has achieved the
"Milestone" under the Stock Purchase Agreement, dated March 5, 2003,
between Interleukin and Alticor. The Milestone is met when Interleukin
enters into a genetic testing agreement with one or more customers of
such size that the projected internal rate of return with respect to
the project is at least 20% with a payback period of three years or
less.
    As a result of the achievement of this Milestone, Alticor has made
an additional $2,000,000 capital contribution to Interleukin with no
additional shares being issued to Alticor.
    "We are extremely pleased to have met this milestone in our
alliance with Alticor," said Philip R. Reilly, MD, JD, Interleukin's
Chief Executive Officer. "This is an important event for the company
as we execute our portion of the collaborative agreement and prepare
for product launch next year."

    About Interleukin Genetics

    Interleukin Genetics is a biotechnology company focused on
inflammation. The company uses functional genomics to help in the
development of risk assessment, nutritional and therapeutic products
based on the genetic variations in people to help prevent, ameliorate
or treat diseases involving inflammation. Interleukin's current
programs focus on cardiovascular disease, osteoporosis, rheumatoid
arthritis and Alzheimer's disease. Interleukin expects that these
programs will produce products that will personalize the selection of
nutritional and therapeutic products and enable the managed care
industry to improve patient care and better allocate resources. For
more information about Interleukin and its ongoing programs, please
visit http://www.ilgenetics.com.

    Certain statements contained herein are "forward-looking"
statements including statements regarding our ability to develop
diagnostic, personalized nutritional and therapeutic products to
prevent or treat diseases of inflammation and to enable the managed
care industry to improve patient care and better allocate resources.
Because such statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements include, but are not limited to, our
ability to develop diagnostic, personalized nutritional and
therapeutic products to prevent or treat diseases of inflammation and
to enable the managed care industry to improve patient care and better
allocate resources and our ability to market such products, our
ability to complete clinical research and data analysis, meeting our
clinical studies' endpoints, risk of market acceptance of our
products, risk of technology and products obsolescence, delays in
development of products, reliance on partners, competitive risks and
those risks and uncertainties described in our Form 10-Q for the three
months ended September 30, 2003, as filed on November 12, 2003, and in
other filings made by us with the Securities and Exchange Commission.
We disclaim any obligation or intention to update these
forward-looking statements.

    CONTACT: Interleukin Genetics, Inc.
             Fenel M. Eloi, 781-398-0700